Poll: 47% of Americans Hesitant to Get Covid-19 Vaccine
Many Americans are hesitant to be vaccinated against Covid-19, according to research from Invisibly.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
Severe allergic reactions to Moderna vaccine appear rare: CDC report
/in Allergic Reactions, Anaphylaxis, BioNTech, Coronavirus Vaccines, Covid-19 Data, Moderna, Pfizer, U.S. Centers for Disease Control and PreventionSevere allergic reactions to Moderna Inc.’s coronavirus vaccine appear to be quite rare, the U.S. Centers for Disease Control and Prevention (CDC) said, after more than 4 million people received their first dose.
Covid-19 Vaccine Runner-Up Update: Who Will Reach the Finish Line Next?
/in Clinical Trials, COVID-19 Vaccines, Johnson & Johnson, R&DWith the Pfizer-BioNTech and Moderna Covid-19 vaccines authorized in the United States and being distributed and dosed, some of the attention is shifting to Johnson & Johnson’s efforts for the company’s one-shot vaccine in hopes to help mitigate some of the country’s distribution problems.
GSK’s Challenging Week: Halted Study, Delayed FDA Decision and Departing Exec
/in Business, Checkpoint Inhibitors, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Departures, EvaluatePharma, FDA, GlaxoSmithKline, Inspections, People on the Move, R&D, Ulcerative Colitis, VaccinesGlaxoSmithKline discontinued a Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody aimed at treating ulcerative colitis licensed from Australia-based Immutep Limited following an interim assessment of an Independent Data Monitoring Committee.
Walmart expands vaccinations in boost to U.S. Covid-19 program
/in Arkansas, Asa Hutchinson (Ark.), Chicago, COVID-19 Vaccinations, CVS Health, Georgia, Indiana, Kroger, Louisiana, Maryland, New Jersey, New Mexico, Pharmacists, Puerto Rico, Rite Aid, South Carolina, Texas, Wal-Mart Stores, Walgreens Boots Alliance, WalmartWalmart Inc. is preparing to offer Covid-19 vaccinations in seven more states, as well as in Chicago and Puerto Rico, expanding beyond the two states where the company’s pharmacists are offering inoculations.
W2O Adds Three New Leaders to Further Drive Digital Transformation in Healthcare
/in Appointments, Business, Digital, Healthcare Communications Agencies, Healthcare Communications Networks, Marketing & Advertising, New Hires, People on the MoveW2O announced the creation of three new positions to lead the global health innovation leader’s continued growth and transformation across the healthcare spectrum.
Gap between Covid-19 shots may be stretched past recommended range in some cases
/in BNT162b2 (Pfizer and BioNTech), Britain, COVID-19 shots, COVID-19 Vaccine Guidance, COVID-19 Vaccines, Dr. Anthony Fauci (Director), Health Officials, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Reuters, U.S. Centers for Disease Control and Prevention, United StatesU.S. public health officials said a second Covid-19 shot could be administered as much as six weeks apart from the first one in situations where it was not possible to get a booster dose immediately.
Special Report: How U.S. CDC missed chances to spot COVID’s silent spread
/in Asymptomatic Patients, CDC Director Robert Redfield, Coronavirus, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Covid-19 Quarantine, Cruise passengers, Japan, Masks, Outbreaks, Reuters, Scientists, U.S. Centers for Disease Control and Prevention, United StatesReuters found new evidence that the U.S. Centers for Disease Control and Prevention’s (CDC) response to the pandemic was marred by actions – or inaction – by the agency’s career scientists and frontline staff.
Study: Eli Lilly’s Covid-19 Antibody Protects the Most Vulnerable from Infection
/in AARP, Bamlanivimab (LY-CoV555), Clinical Data, Clinical Trials, Coronavirus Infections, COVID-19 Antibodies, COVID-19 risk, Monoclonal Antibodies, Nursing Homes, Placebo, R&DProtecting the most vulnerable, Eli Lilly’s bamlanivimab significantly reduced Covid-19 risk for nursing home residents in a Phase III trial.
FDA approves ViiV’s Cabenuva as first complete long-acting regimen for HIV treatment
/in Adults, Antiretrovirals, Approvals, Clinical Trials, FDA, First-In-Class, GlaxoSmithKline, HIV-1, New Drug Applications, Patient Assistance Programs, R&D, TherapeuticsThe U.S. Food and Drug Administration approved ViiV Healthcare’s Cabenuva as the only complete long-acting regimen for the treatment of HIV-1 infection in adults.